तुलना करने के लिए मीट्रिक्स | 378800 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध378800पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −5.7x | −14.9x | −0.5x | |
PEG अनुपात | −0.43 | −0.21 | 0.00 | |
क़ीमत/बुक | 3.5x | 3.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 385.3x | 11.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 20.1% | 50.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.8% | 7.7% | अनलॉक करें |
Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuPulin for the treatment of inflammation-driven pulmonary fibrosis. In addition, it offers Papiliximab, a NanoMab-based bispecific antibody that blocks PD-L1 and CD47 for leukemia treatment; Ovizumab, a tumor-specific immunotherapy; Regtizumab, an anti-tumor immunity; and Rbody, a NanoMabs’ small size which enables the creation of LNP-mRNA therapeutics. Further, the company provides RumiLua, a cosmeceutical ingredient to help prevent excessive skin responses while supporting the skin’s natural balance and overall condition. The company was founded in 2008 and is headquartered in Seoul, South Korea.